Neurizon Therapeutics (ASX:NUZ): HEALEY Phase 2/3 ALS Trial Fully Recruited | 2027 Readout

Can Neurizon Therapeutics (ASX:NUZ) deliver a meaningful new treatment option for ALS, the most common form of motor neuron disease? In this Homodeus Research webinar, Interim Executive Chair Sergio Duchini and CFO Dan O'Connell discuss NUZ-001 and the fully recruited Phase 2/3 HEALEY ALS Platform Trial in the United States. The conversation covers the 250-patient HEALEY study, the anticipated 2027 clinical readout, encouraging signals from the earlier Phase 1 MEND study, the NIH-funded Expanded Access Program, clinical endpoints and biomarker strategy, incoming CEO Dr Chris Bremmer, funding, manufacturing and Neurizon's preparations for potential commercialisation. The webinar also explores the mechanism of action of NUZ-001, regulatory strategy, Neurizon's relationship with Elanco and the key milestones investors should watch as the program progresses toward its defining clinical readout. TIMESTAMPS 00:00 Introduction 01:23 Neurizon Overview & Leadership 03:03 Phase 2/3 ALS Trial & 2027 Readout 04:00 ALS/MND: Unmet Need & Market Opportunity 05:00 Why NUZ-001 Is at a Critical Stage 07:39 Incoming CEO Dr Chris Bremmer 10:17 HEALEY ALS Platform Trial Explained 12:48 Biomarker Strategy & Trial Data 15:01 Phase 2/3 Trial Design 18:58 Primary & Secondary Clinical Endpoints 20:28 NIH-Funded Expanded Access Program 23:21 Phase 1 MEND Study Results 27:00 How NUZ-001 Works 30:53 Funding & Capital Management 34:25 Elanco Partnership, Manufacturing & Commercial Readiness 37:26 Catalysts Ahead of the 2027 Readout 40:19 Investor Q&A 43:21 What Could Support FDA Approval? 45:53 Expanded Access Data & FDA Strategy 50:56 Elanco Manufacturing & Regulatory Questions ABOUT HOMODEUS RESEARCH Homodeus Research provides independent investor education through in-depth interviews with ASX-listed companies, fund managers and industry experts, helping investors better understand businesses, industries and long-term investment opportunities. Enjoyed this interview? Subscribe to Homodeus Research for interviews with ASX-listed executives, industry experts and thought leaders across healthcare, biotechnology, technology, mining and emerging growth companies. DISCLAIMER This webinar is provided for educational purposes only and should not be considered financial advice. Always conduct your own research and seek advice from a licensed financial adviser before making investment decisions.